Advancing Alzheimer’s trials through smarter imaging

Latest data from our partner Quantified Imaging demonstrate that ASL‑MRI can reveal treatment response to Lecanemab after just 2 months. These perfusion‑based biomarkers show strong alignment with long‑term cognitive outcomes — a major step toward more reliable and efficient trial design.

In a field challenged by complex biology and heterogeneous patient profiles, advanced imaging offers a clearer, earlier window into therapeutic impact.

Wemedoo and mediri are hosting a joint 30‑minute live webinar, bringing together clinical, imaging, and data perspectives to examine why Alzheimer’s trials so often fall short — and what can be done differently.

Speakers:
Prof. Dr. Matthias Guenther, Founder & CEO, mediri
Dr. Nikola Cihoric, MD, RO, Founder & Chief Product Officer, Wemedoo

Live Webinar
January 29, 2026
12:00 – 12:30 CET

Join us to explore how imaging innovation can accelerate Alzheimer’s research.
Webinar LINK